Sign In
Buy NBTX
$38.39
-1.77 (-4.41%)
At Close: Jul 31, 2026
Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Given Average Rating of “Moderate Buy” by Analysts
04:22am, Friday, 24'th Apr 2026
Shares of Nanobiotix S.A. - Sponsored ADR (NASDAQ: NBTX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the five analysts that are currently covering the company, Ma
Preclinical evaluation in mice assessed the potential of the Nanobiotix Nanoprimer to overcome common barriers faced by lipid nanoparticle(“LNP”)-delivered therapies related to rapid liver clearan
Nanobiotix (NASDAQ:NBTX) versus NRx Pharmaceuticals (NASDAQ:NRXP) Financial Contrast
01:28am, Friday, 17'th Apr 2026
Nanobiotix (NASDAQ: NBTX - Get Free Report) and NRx Pharmaceuticals (NASDAQ: NRXP - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two bus
Voting Rights and Shares Capital of the Company
04:15pm, Tuesday, 07'th Apr 2026
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) In accordance wi
Nanobiotix (NASDAQ:NBTX) Shares Gap Down – Here’s What Happened
03:49am, Saturday, 04'th Apr 2026
Nanobiotix S.A. - Sponsored ADR (NASDAQ: NBTX - Get Free Report) shares gapped down prior to trading on Thursday. The stock had previously closed at $34.07, but opened at $31.03. Nanobiotix shares las
Nanobiotix H2 Earnings Call Highlights
01:07am, Friday, 03'rd Apr 2026
Nanobiotix (NASDAQ: NBTX) executives said the company made "a very rich" set of operational and financial moves in 2025, highlighting progress in its Johnson and Johnson collaboration around NBTXR3/JN
Nanobiotix S.A. (NBTX) Q4 2025 Earnings Call Transcript
02:02pm, Wednesday, 01'st Apr 2026
Nanobiotix S.A. (NBTX) Q4 2025 Earnings Call Transcript
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results
04:15pm, Tuesday, 31'st Mar 2026
Global development program for JNJ-1900 (NBTXR3) proceeded as planned, building toward opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck can
NANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026
04:15pm, Thursday, 26'th Mar 2026
Conference call and webcast scheduled for Wednesday, April 1st, 2026, at 8:00 am EDT / 2:00 pm CEST Conference call and webcast scheduled for Wednesday, April 1st, 2026, at 8:00 am EDT / 2:00 pm CEST
Cancer Drug Developer Nanobiotix Denies Any Active Takeover Process
01:02pm, Wednesday, 25'th Mar 2026
The stock's movement follows a statement clarifying that there is no ongoing process or assessment for a takeover, which has helped to stabilize investor sentiment as broader markets are experiencing
NANOBIOTIX Statement Regarding Recent Media Speculation
10:11am, Wednesday, 25'th Mar 2026
PARIS and CAMBRIDGE, Mass., March 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic ap
Nanobiotix (NASDAQ:NBTX) Shares Gap Up – Here’s What Happened
01:41am, Sunday, 15'th Mar 2026
Nanobiotix S.A. - Sponsored ADR (NASDAQ: NBTX - Get Free Report)'s share price gapped up prior to trading on Friday. The stock had previously closed at $31.52, but opened at $35.28. Nanobiotix shares
Voting Rights and Shares Capital of the Company
04:15pm, Thursday, 12'th Mar 2026
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)
Nanobiotix (NASDAQ:NBTX) Hits New 1-Year High – Time to Buy?
01:36am, Monday, 02'nd Mar 2026
Nanobiotix S.A. - Sponsored ADR (NASDAQ: NBTX - Get Free Report) hit a new 52-week high during trading on Saturday. The stock traded as high as $31.62 and last traded at $31.04, with a volume of 86067
NANOBIOTIX to Participate in Investor Conferences in March
04:15pm, Wednesday, 25'th Feb 2026
PARIS and CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic app
